JP2020518650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518650A5 JP2020518650A5 JP2019561267A JP2019561267A JP2020518650A5 JP 2020518650 A5 JP2020518650 A5 JP 2020518650A5 JP 2019561267 A JP2019561267 A JP 2019561267A JP 2019561267 A JP2019561267 A JP 2019561267A JP 2020518650 A5 JP2020518650 A5 JP 2020518650A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- mab
- antibody fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193173A JP7641262B2 (ja) | 2017-05-08 | 2022-12-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
| JP2024014044A JP2024032937A (ja) | 2017-05-08 | 2024-02-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503315P | 2017-05-08 | 2017-05-08 | |
| US62/503,315 | 2017-05-08 | ||
| PCT/US2018/031705 WO2018208864A1 (en) | 2017-05-08 | 2018-05-08 | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193173A Division JP7641262B2 (ja) | 2017-05-08 | 2022-12-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518650A JP2020518650A (ja) | 2020-06-25 |
| JP2020518650A5 true JP2020518650A5 (enExample) | 2021-05-27 |
| JP7393207B2 JP7393207B2 (ja) | 2023-12-06 |
Family
ID=64104990
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561267A Active JP7393207B2 (ja) | 2017-05-08 | 2018-05-08 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
| JP2022193173A Active JP7641262B2 (ja) | 2017-05-08 | 2022-12-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
| JP2024014044A Pending JP2024032937A (ja) | 2017-05-08 | 2024-02-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193173A Active JP7641262B2 (ja) | 2017-05-08 | 2022-12-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
| JP2024014044A Pending JP2024032937A (ja) | 2017-05-08 | 2024-02-01 | 抗ｃｄ３結合ドメインおよび当該ドメインを含有する抗体、ならびにそれらの作製方法および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11542330B2 (enExample) |
| EP (1) | EP3621641A4 (enExample) |
| JP (3) | JP7393207B2 (enExample) |
| KR (2) | KR20250121461A (enExample) |
| CN (4) | CN118894936A (enExample) |
| AU (2) | AU2018266711B2 (enExample) |
| BR (1) | BR112019023111A2 (enExample) |
| CA (1) | CA3062825A1 (enExample) |
| IL (2) | IL322042A (enExample) |
| MX (2) | MX2019013184A (enExample) |
| SG (2) | SG11201910096RA (enExample) |
| WO (1) | WO2018208864A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021014973A (es) * | 2019-06-07 | 2022-04-18 | Adimab Llc | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. |
| CN119874917A (zh) * | 2019-06-07 | 2025-04-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| KR20220045030A (ko) * | 2019-08-17 | 2022-04-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 |
| US20210087271A1 (en) * | 2019-09-20 | 2021-03-25 | Adimab, Llc | Fc variants with reduced effector function |
| AU2020403913B2 (en) | 2019-12-18 | 2024-10-10 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
| WO2021154534A1 (en) * | 2020-01-28 | 2021-08-05 | Promab Biotechnologies, Inc. | Plap-cd3 epsilon bispecific antibodies |
| MX2022013499A (es) * | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Bibliotecas de ácidos nucleicos variantes para coronavirus. |
| CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
| US20230374162A1 (en) * | 2020-10-07 | 2023-11-23 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
| CN114539415B (zh) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 |
| CN112578117B (zh) * | 2021-02-22 | 2021-05-25 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用 |
| CN112698044B (zh) * | 2021-03-23 | 2021-06-22 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 靶向治疗后免疫状态评价装置及方法 |
| EP4380631A4 (en) * | 2021-08-04 | 2025-06-25 | Abpro Corporation | Cd3 targeting antibodies and uses thereof |
| EP4377360A4 (en) * | 2021-09-17 | 2025-10-15 | Adimab Llc | Anti-cd3 antibodies |
| EP4413044A4 (en) * | 2021-10-07 | 2025-10-22 | Nat Res Council Canada | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS |
| WO2023060277A1 (en) * | 2021-10-08 | 2023-04-13 | Arbele Limited | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof |
| CN114573705B (zh) * | 2022-03-17 | 2024-05-14 | 杭州师范大学 | 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| CN116925232A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 靶向ceacam和cd3的多特异性抗体及其用途 |
| CN115453124B (zh) * | 2022-08-01 | 2025-11-25 | 中国科学院高能物理研究所 | 一种纳米颗粒表面多层蛋白冠成分的原位鉴定与定量方法 |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN115960243B (zh) * | 2023-01-09 | 2025-05-06 | 中国药科大学 | 靶向cd24和cd3的双特异性抗体及其应用 |
| WO2024206568A2 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025230233A1 (ko) * | 2024-05-03 | 2025-11-06 | 국민대학교산학협력단 | 인간 cd3에 특이적인 항체 및 이의 용도 |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1629011T3 (da) * | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| SG182408A1 (en) * | 2010-01-11 | 2012-08-30 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| HUE037720T2 (hu) * | 2012-03-28 | 2018-09-28 | Sanofi Sa | Bradikinin B1 receptor ligandumok elleni antitestek |
| ME03675B (me) * | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| PT3221356T (pt) * | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| CN120988137A (zh) * | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| EP3091032A1 (en) * | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
-
2018
- 2018-05-08 CN CN202410287656.XA patent/CN118894936A/zh active Pending
- 2018-05-08 CN CN201880045633.0A patent/CN110913895B/zh active Active
- 2018-05-08 IL IL322042A patent/IL322042A/en unknown
- 2018-05-08 SG SG11201910096R patent/SG11201910096RA/en unknown
- 2018-05-08 SG SG10201912494TA patent/SG10201912494TA/en unknown
- 2018-05-08 CN CN202410287712.XA patent/CN118562001A/zh active Pending
- 2018-05-08 JP JP2019561267A patent/JP7393207B2/ja active Active
- 2018-05-08 WO PCT/US2018/031705 patent/WO2018208864A1/en not_active Ceased
- 2018-05-08 KR KR1020257026024A patent/KR20250121461A/ko active Pending
- 2018-05-08 EP EP18798898.5A patent/EP3621641A4/en active Pending
- 2018-05-08 CA CA3062825A patent/CA3062825A1/en active Pending
- 2018-05-08 IL IL270366A patent/IL270366B2/en unknown
- 2018-05-08 KR KR1020197036219A patent/KR102844399B1/ko active Active
- 2018-05-08 AU AU2018266711A patent/AU2018266711B2/en active Active
- 2018-05-08 US US16/611,832 patent/US11542330B2/en active Active
- 2018-05-08 BR BR112019023111-0A patent/BR112019023111A2/pt unknown
- 2018-05-08 MX MX2019013184A patent/MX2019013184A/es unknown
- 2018-05-08 CN CN202410287775.5A patent/CN118184781A/zh active Pending
-
2019
- 2019-11-05 MX MX2024005009A patent/MX2024005009A/es unknown
-
2022
- 2022-11-11 US US18/054,588 patent/US20230151097A1/en active Pending
- 2022-12-01 JP JP2022193173A patent/JP7641262B2/ja active Active
-
2024
- 2024-02-01 JP JP2024014044A patent/JP2024032937A/ja active Pending
-
2025
- 2025-04-30 AU AU2025203086A patent/AU2025203086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518650A5 (enExample) | ||
| IL270366B1 (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| US9534056B2 (en) | Engineered TAA antibody-TNFSF member ligand fusion molecules | |
| CN116096741B (zh) | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 | |
| JP2024534454A5 (enExample) | ||
| US20230348577A1 (en) | Modified fc regions | |
| US20250197478A1 (en) | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use | |
| US20230365694A1 (en) | IMMUNOSILENCING Fc VARIANTS | |
| KR20250130357A (ko) | 신생아 fc 수용체 (fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 | |
| US20250163166A1 (en) | Antibody comprising igg fc region variant, and use thereof | |
| RU2021138136A (ru) | Высокоаффинные антитела к cd3 и способы их получения и применения | |
| RU2024136825A (ru) | Высокоаффинные антитела к cd3 и способы их получения и применения | |
| RU2024136954A (ru) | Сконструированные ph-зависимые антитела к cd3, а также способы их получения и применения | |
| RU2021138150A (ru) | Сконструированные ph-зависимые антитела к cd3, а также способы их получения и применения | |
| RU2024109201A (ru) | Антитела к cd3 | |
| KR20250151402A (ko) | 반려 동물에서 사용하기 위한 이중특이적 결합제 | |
| HK40115880A (zh) | 具有与fcgammar和c1q的消除的结合的fc变体 | |
| WO2025203029A1 (en) | Tricer - a tri-specific cell engager and retainer | |
| HK40115364A (zh) | 具有与fcgammar和c1q的消除的结合的fc变体 | |
| HK40085105A (en) | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |